Login / Signup

Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents.

Hideaki MiyakeRyo SatoKyohei WatanabeYuto MatsushitaHiromitsu WatanabeDaisuke MotoyamaToshiki ItoTakayuki SugiyamaAtsushi Otsuka
Published in: International journal of clinical oncology (2021)
The introduction of cabazitaxel as a third-line agent could markedly improve the prognostic outcomes of mCRPC patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • adipose tissue
  • patient reported outcomes
  • replacement therapy
  • patient reported